Fox04-DRI

FOXO4-DRI is a D-retro-inverso (DRI) peptide designed to disrupt the interaction between FOXO4 and p53 in senescent cells. Developed by Baar et al. at Erasmus University Medical Center in the Netherlands, the peptide is based on the FOXO4 domain that binds p53, but synthesized with D-amino acids in reverse order to create a protease-resistant mirror image that retains binding activity. In senescent cells, FOXO4 sequesters p53 in PML nuclear bodies, preventing p53-mediated apoptosis and allowing senescent cells to remain viable despite growth arrest. FOXO4-DRI was designed to compete with endogenous FOXO4 for p53 binding, releasing p53 to activate apoptotic pathways selectively in senescent cells. This approach has been described as a “senolytic” strategy — selectively eliminating senescent cells while sparing non-senescent cells that do not depend on the FOXO4-p53 interaction for survival.

FOXO4-DRI has been investigated for its selective disruption of the FOXO4-p53 protein-protein interaction in senescent cells. In the senescent state, FOXO4 accumulates in PML (promyelocytic leukemia) nuclear bodies where it binds and sequesters p53, preventing p53 from activating the mitochondrial apoptotic pathway. Researchers observed that FOXO4-DRI, as a D-retro-inverso peptide, competes with endogenous FOXO4 for p53 binding while resisting proteolytic degradation. Studies suggest that by displacing FOXO4, the peptide releases p53 to translocate to the cytoplasm and mitochondria, where it activates Bax/Bak pore formation and caspase-mediated apoptosis. Critically, this mechanism is selective for senescent cells because non-senescent cells do not accumulate FOXO4 in PML bodies and do not depend on FOXO4-p53 sequestration for survival. In aged mouse models, researchers observed that FOXO4-DRI administration was associated with changes in senescence biomarker levels and functional parameters.

Discovery and In Vivo Studies

Baar et al. (2017) designed and characterized FOXO4-DRI and demonstrated its selective activity against senescent cells in culture and in naturally aged mice. Researchers observed that treatment was associated with reduced p16-positive cell populations and changes in physical function parameters in aged animals [1].

Senescence and p53

Demaria et al. (2014) characterized the role of senescent cells in tissue biology, demonstrating that senescent cell accumulation is associated with functional changes in aging tissues and providing the rationale for senolytic approaches [2].

D-Retro-Inverso Peptide Design

Baar et al. (2017) described the D-retro-inverso modification strategy that confers protease resistance while maintaining the binding surface topology needed for p53 interaction, establishing the pharmaceutical chemistry basis for FOXO4-DRI [1].